| 瑞马唑仑临床应用研究进展 |
| 投稿时间：2024-05-11 修订日期：2024-07-18 点此下载全文 |
| 引用本文：杨凤艳,张月,陈恩贤,缪雪蓉,魏凯.瑞马唑仑临床应用研究进展[J].药学实践杂志,2024,42(9):365~374 |
| 摘要点击次数: 532 |
| 全文下载次数: 1134 |
|
| 基金项目:海军军医大学校级基础医学研究课题青年启动基金（2023QN035）；上海市老龄化和妇儿健康研究专项（2020YJZX0133）；上海市卫健委临床研究专项（20224Y0254） |
|
| 中文摘要:瑞马唑仑是一种新型超短效苯二氮?类药物，通过作用于γ-氨基丁酸A型（GABAA）受体而产生镇静作用。瑞马唑仑起效快、半衰期短、清除率高、体内无蓄积、注射疼痛发生率低、对肝肾功能、呼吸及血流动力学影响较轻，且可被氟马西尼迅速逆转。综述瑞马唑仑在程序性镇静、全麻诱导与维持等领域的临床研究进展，旨在为其临床应用提供依据。 |
| 中文关键词:瑞马唑仑 程序性镇静 麻醉 苯二氮?类药物 |
| |
| Research progress on the clinical application of remazolam |
|
|
| Abstract:Remazolam is a new ultra-short-acting benzodiazepine that produces sedation by acting on γ-aminobutyric acid type A（GABAA）receptors. Remazolam has characteristics of rapid onset of action, short half-life, high clearance, and no accumulation in the body. It also has a low incidence of injection pain and mild effects on hepatic and renal function, respiration, and haemodynamics. Additionally, it can be rapidly reversed by flumazenil. The clinical research progress on remazolam in the areas of procedural sedation, induction, and maintenance of general anesthesia were reviewed to provide references for its clinical application. |
| keywords:remazolam procedural sedation anaesthesia benzodiazepines |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
